

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,221	08/04/2003	Peter D. Roberts	LSBC-0137-CP04B	1497
25871	7590 07/17/2006		EXAM	INER
SWANSON & BRATSCHUN L.L.C. 1745 SHEA CENTER DRIVE			ZHENG, LI	
SUITE 330			ART UNIT	PAPER NUMBER
HIGHLANDS	RANCH, CO 80129		1638	
			DATE MAILED: 07/17/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Comments	10/634,221	ROBERTS ET AL.					
Office Action Summary	Examiner	Art Unit					
	Li Zheng	1638					
The MAILING DATE of this communication apperiod for Reply	pears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 04 A	Responsive to communication(s) filed on 04 August 2003.						
· <u> </u>	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4)⊠ Claim(s) 3-25,27-29 and 31-37 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>3-25,27-29 and 31-37</u> are subject to	restriction and/or election requirer	nent.					
Application Papers	•	•					
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
 Certified copies of the priority documents have been received. 							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Burea	` ''						
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)	•						
1) Notice of References Cited (PTO-892)	4) Interview Summary						
 Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 	Paper No(s)/Mail Da 5) Notice of Informal P	ate atent Application (PTO-152)					
Paper No(s)/Mail Date 6) Other:							

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 3, 6-25, 27, 32 and 36, drawn to a bipartite RNA viral vector comprising modified tobravirus RNA-1 and modified tobravirus RNA-2, classified in class 435, subclass 320.1, for example.
- II. Claims 4, 5-23, 28-29, 31-33 and 36, drawn to a bipartite RNA viral vector comprising unmodified tobravirus RNA-1 and modified tobravirus RNA-2, classified in class 435, subclass 468, for example.
- III. Claims 34, 35 and 37, drawn to methods of compiling a plant functional gene profile or determining the presence of a trait in a plant, classified in class 800, subclass 278, for example.

Inventions I-II and invention III are patentably distinct. Inventions I-II are drawn to bipartite RNA viral vectors from modified tobravirus. Invention III is drawn to methods of compiling a plant functional gene profile or determining the presence of a trait in a plant using recombinant viral nucleotide sequence from tobravirus which including any type of recombinant viral vectors such as monopartite RNA viral vector. The method of invention III is designed to screen for phenotypes by transient expression of an unknown insert whereas bipartite RNA vectors of inventions I-II could be used to infect

Art Unit: 1638

the plants systemically. Furthermore, searching invention I-II and inventions III together would impose an undue search burden. In the instant case, prior art search for the different steps used in the methods are not coextensive. A search of each of these inventions would require different key word searches of each compound, and each step, of the methods, using divergent patent and non-patent literature databases. The different searches would then require subsequent in-depth analysis of the unrelated prior art literature, placing a serious burden on the Office in terms of both search and examination.

Inventions I and II are related as products which share an alleged common utility of expressing foreign RNA but the common utility is not linked to a substantial structural feature. The products in this relationship are distinct if either or both of the following can be shown: (1) that the products encompass embodiments that are not required to perform the common utility or (2) that the products as claimed can be used to perform another utility. In this case, the vector of invention I is drawn to a bipartite RNA viral vector comprising modified tobravirus RNA-1 and modified tobravirus RNA-2 used to express two foreign RNAs. The vector of invention I is drawn to a bipartite RNA viral vector comprising unmodified tobravirus RNA-1 and modified tobravirus RNA-2 used to express only one foreign RNA. The unmodified RNA-1 and modified RNA-1 are structurally distinct from each other. Furthermore, searching invention I and II together would impose an undue search burden. In the instant case, prior art search for the different tobravirus RNA-1 are not coextensive. A search of each of these inventions would require different key word searches of each compound, and each step, of the

methods, using divergent patent and non-patent literature databases. The different searches would then require subsequent in-depth analysis of the unrelated prior art literature, placing a serious burden on the Office in terms of both search and examination.

Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of

Art Unit: 1638

record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Li Zheng whose telephone number is 571-272-8031.

The examiner can normally be reached on Monday through Friday 9:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ASHWIN D. MENTA, PH.D. PRIMARY EXAMINER